Latest posts
-
Oncocyte Reports Third Quarter 2023 Financial Results
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights Josh Riggs, CEO
-
Oncocyte to Announce Third Quarter 2023 Financial Results
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m.
-
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
NEW YORK, NY, October 24, 2023 – The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with
-
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”
October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c.,
-
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The
-
Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”] Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data
-
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh
-
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft
-
Oncocyte Reports Second Quarter 2023 Financial Results
Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights “In the second quarter, we made significant progress
-
ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS
IRVINE, CA, August 9, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The